Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More
Xconomy
NOVEMBER 8, 2019
Those drugs have now become the center of a patent dispute between the Foster City, CA, drug maker and the federal government. This week, the government filed a patent infringement suit in federal court against Gilead (NASDAQ: GILD ).
Let's personalize your content